Clinical trial · Interventional
Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
Anlotinib Hydrochloride Combined With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Small Cell Lung Cancer
NCT06611657CI-TRIAL-00081617active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Whole Brain Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Antirotinib hydrochloride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Anlotinib hydrochloride
- description
- Subjects received antirotinib hydrochloride capsules, 1 capsule (12mg) once a day.
- interventionNames
- Drug: Antirotinib hydrochloride
Primary outcomes (1)
- measure
- Intracranial progression-free survival
- timeFrame
- 6 months
- description
- Time from enrollment to intracranial tumor progression or death
Secondary outcomes (2)
- measure
- Overall Survival
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria. 2. The expected survival time is more than 3 months. 3. Intracranial metastases ≤10. 4. Adequate organ and bone marrow function. Exclusion Criteria: 1. Patients who have used antiangiogenic drugs within the previous 1 month. 2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer). 3. Small cell lung cancer with hilar invasion or hemoptysis. 4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage. 5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment. 6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications. 7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.
References
Publications (0)
Data not yet available
No reference posted for this study.